[Modification of hypofibrinolytic states by dehydrochlormethyltestosterone].
Twenty patients with established diagnosis of insufficient fibrinolysis were treated with dehydrochlormethyl-testosterone (Turinabol). Doses of 5 or 10 mg per day, resp. were administered orally. Four weeks after the beginning of treatment the fibrinolytic capacity began to increase and reached a maximum in the 3rd and 4th months of treatment. In one patient with thrombotic tendency it disappeared under medication, however, after withdrawal of the drug it appeared anew. Side effects were roughness of the voice in two patients and slight weight gain in one patient.
D000328:Adult; D000990:Antithrombin III / Q000378:metabolism; D005260:Female; D005342:Fibrinolysis / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010960:Plasminogen Activators / Q000378:metabolism; D013739:Testosterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013923:Thromboembolism / Q000097:blood / Q000188:drug therapy* / Q000235:genetics
C000430:D-4-chloro-17 beta-hydroxy-3-oxo-17 alpha-methylandrosta-1,4-diene; D013739:Testosterone; D000990:Antithrombin III; D010960:Plasminogen Activators
Beeinflussung hypofibrinolytischer Zustände durch Dehydrochlormethyltestosteron.